Bosl GJ - Search Results

1

Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.

Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ. Bajorin DF, et al. Among authors: bosl gj. J Clin Oncol. 1995 Jan;13(1):79-86. doi: 10.1200/JCO.1995.13.1.79. J Clin Oncol. 1995. PMID: 7799046 Clinical Trial.

2

The late effects of germ cell tumor chemotherapy: more data are needed.

Bosl GJ. Bosl GJ. J Clin Oncol. 1992 Sep;10(9):1375-6. doi: 10.1200/JCO.1992.10.9.1375. J Clin Oncol. 1992. PMID: 1325538 No abstract available.

3

High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions.

Motzer RJ, Bosl GJ. Motzer RJ, et al. Among authors: bosl gj. J Natl Cancer Inst. 1992 Nov 18;84(22):1703-9. doi: 10.1093/jnci/84.22.1703. J Natl Cancer Inst. 1992. PMID: 1331482 Review.

4

Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ. Motzer RJ, et al. Among authors: bosl gj. Semin Oncol. 1992 Dec;19(6 Suppl 12):8-11. Semin Oncol. 1992. PMID: 1336624

5

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.

Murphy BA, Motzer RJ, Bosl GJ. Murphy BA, et al. Among authors: bosl gj. Invest New Drugs. 1992 Nov;10(4):327-30. doi: 10.1007/BF00944190. Invest New Drugs. 1992. PMID: 1336770 Clinical Trial.

6

Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.

Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Bajorin DF, et al. Among authors: bosl gj. Semin Oncol. 1992 Apr;19(2):148-58. Semin Oncol. 1992. PMID: 1372757 Review.

7

"Poor-risk" germ cell tumors: current progress and future directions.

Motzer RJ, Bajorin DF, Bosl GJ. Motzer RJ, et al. Among authors: bosl gj. Semin Oncol. 1992 Apr;19(2):206-14. Semin Oncol. 1992. PMID: 1372761 Review. No abstract available.

8

Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.

Wood DP Jr, Herr HW, Motzer RJ, Reuter V, Sogani PC, Morse MJ, Bosl GJ. Wood DP Jr, et al. Among authors: bosl gj. Cancer. 1992 Nov 1;70(9):2354-7. doi: 10.1002/1097-0142(19921101)70:9<2354::aid-cncr2820700924>3.0.co;2-u. Cancer. 1992. PMID: 1382832

9

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: bosl gj. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

10

Continued refinement in the treatment of germ cell tumour patients.

Bajorin DF, Bosl GJ. Bajorin DF, et al. Among authors: bosl gj. Eur J Cancer. 1991;27(6):677-8. doi: 10.1016/0277-5379(91)90162-7. Eur J Cancer. 1991. PMID: 1648942 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

326 results

Search Page